[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580206":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":38,"responsibleParty":111,"collaborators":26,"id":113,"slug":26,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":114,"sex":120,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":26,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":66,"whyStopped":26,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"CERo Therapeutics Holdings, Inc.","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Single Agent CER-1236","EXPERIMENTAL","AML patient treated with a single dose of CER-1236 monotherapy",[13,14,15,16],"Drug: CER-1236","Drug: Cyclophosphamide","Drug: Fludarabine","Drug: Mesna",{"label":18,"type":10,"description":11,"interventionNames":19},"Part 2: Single Agent CER-1236",[13,14,15,16],[21,27,31,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","CER-1236","an autologous chimeric engulfment receptor T-cell",[9,18],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Cyclophosphamide","Lymphodepleting chemotherapy",[9,18],{"type":22,"name":32,"description":29,"armGroupLabels":33,"otherNames":26},"Fludarabine",[9,18],{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":26},"Mesna","Chemoprotectant",[9,18],[39,64,81,95],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University of California, Davis Comprehensive Cancer Center","NOT_YET_RECRUITING","Sacramento","California","95817","United States",{"type":47,"coordinates":48},"Point",[49,50],-121.4944,38.58157,{"lat":50,"lon":49},[53,58,62],{"name":54,"role":55,"phone":56,"phoneExt":26,"email":57},"Brian Jonas, MD","CONTACT","916-382-6970","bajonas@health.ucdavis.edu",{"name":59,"role":55,"phone":60,"phoneExt":26,"email":61},"Alpha Stem Cell Clinic","916-734-","OCRReferral@health.ucdavis.edu",{"name":54,"role":63,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":45,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Colorado Blood Cancer Institute","RECRUITING","Denver","Colorado","80218",{"type":47,"coordinates":71},[72,73],-104.9847,39.73915,{"lat":73,"lon":72},[76,79],{"name":77,"role":55,"phone":26,"phoneExt":26,"email":78},"Maris Michael, MD","PSLMDLCBCINewClinicPatient@HCAHealthcare.com",{"name":80,"role":63,"phone":26,"phoneExt":26,"email":26},"Michael Maris, MD",{"facility":82,"status":66,"city":83,"state":84,"zip":85,"country":45,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Sarah Cannon Research Insitute","Nashville","Tennessee","37203",{"type":47,"coordinates":87},[88,89],-86.78444,36.16589,{"lat":89,"lon":88},[92],{"name":93,"role":55,"phone":94,"phoneExt":26,"email":26},"AskSarah Help Line Have Cancer Questions? askSARAH | Sarah Cannon","844-482-4812",{"facility":96,"status":66,"city":97,"state":98,"zip":99,"country":45,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":47,"coordinates":101},[102,103],-95.36327,29.76328,{"lat":103,"lon":102},[106,110],{"name":107,"role":55,"phone":108,"phoneExt":26,"email":109},"Abhishek Maiti, MD","713-745-3228","amaiti@mdanderson.org",{"name":107,"role":63,"phone":26,"phoneExt":26,"email":26},{"type":112,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100580206",false,"NCT06834282","CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","Phase 1\u002F1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)","CertainT-1","Inclusion Criteria:\n\n* Patients need to have a confirmed diagnosis of de novo or secondary AML, or myelodysplastic syndrome (MDS)\u002FAML with 10% to 19% blasts, per the International Consensus Classification 2022 or the WHO 2022 classification.\n* Absolute lymphocyte count \\>0.3 x 109\u002FL prior to apheresis.\n* Eastern cooperative oncology group (ECOG) performance status 0 to 1.\n\nExclusion Criteria:\n\n* Prior therapy with a permanently integrated, genetically modified cell product.\n* No measurable leukemia on the screening bone marrow evaluation prior to any bridging therapy.\n* Active autoimmune disease or history of autoimmune disease requiring treatment within the prior 2 years. Patients with history of autoimmune thyroiditis or type 1 diabetes well controlled on replacement regimen are eligible.\n* A known hypersensitivity or severe allergy to fludarabine, cyclophosphamide, or study drug components or diluents.\n* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the physician.\n* Primary immunodeficiency disorder.","ALL","18 Years","85 Years",{"count":124,"type":125},18,"ESTIMATED","INTERVENTIONAL",[128],"PHASE1","This is a first in human, multi center, open label, phase 1\u002F1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed\u002Frefractory (R\u002FR), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.",[131,132,133],"AML","Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[135],"Relapsed Acute Myeloid Leukemia","2026-03-23",{"date":138,"type":139},"2026-03-27","ACTUAL",{"date":141,"type":139},"2025-04-07",{"date":143,"type":125},"2029-12-31",{"name":5,"class":6},4]